webmaster

17

Apr2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

0  
April 17, 2023

27

Mar2023

Mohammad Hirmand, MD

0  
Dr. Hirmand has served on the Company’s board of directors since March of 2023 and is a co-founder of Avenzo Therapeutics, a privately held oncology company, and serves as its executive vice president and chief medical officer.  Previously, Dr. Hirmand served as executive vice president and chief medical officer of Turning ... Read More
March 27, 2023

13

Feb2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
February 13, 2023
Dave-Lennon

02

Oct2021

Dave Lennon

0  
Dr. Lennon joined Aadi in October 2023 as President and CEO and member of the board of directors. Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology and non-oncology mTOR-driven diseases. Dr. Lennon joins ... Read More
October 2, 2021